NCT06540833 - A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Biotech Hunter

Enrollment

370

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

October 31, 2027

Conditions

Psychosis Associated With Alzheimer's Disease

Interventions

DRUG

ITI-1284

ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration

DRUG

Placebo

Placebo rapidly disintegrating tablet, taken once daily, sublingual administration

Trial Locations (16)

32751

RECRUITING

Clinical Site, Maitland

32807

NOT_YET_RECRUITING

Clinical Site, Orlando

33012

NOT_YET_RECRUITING

Clinical Site, Hialeah

33032

NOT_YET_RECRUITING

Clinical Site, Miami

33067

NOT_YET_RECRUITING

Clinical Site, Coral Springs

33144

RECRUITING

Clinical Site, Miami

33155

RECRUITING

Clinical Site, Miami

33156

NOT_YET_RECRUITING

Clinical Site, Miami

33166

RECRUITING

Clinical Site, Miami Springs

33445

RECRUITING

Clinical Site, Delray Beach

34239

NOT_YET_RECRUITING

Clinical Site, Sarasota

90720

RECRUITING

Clinical Site, Los Alamitos

92626

RECRUITING

Clinical Site, Costa Mesa

92660

NOT_YET_RECRUITING

Clinical Site, Newport Beach

92805

RECRUITING

Clinical Site, Anaheim

08755

RECRUITING

Clinical Site, Toms River